NeuroBo Pharmaceuticals, Inc. (NRBO)
NRBO moved a median of +0.52% 30 minutes after news, and -0.41% by the close. How NRBO actually reacts to news — the realized, point-in-time move the market made, measured across 132 labeled events over the last three years with zero look-ahead.
NRBO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 98 |
| 30-min | +0.52% | 56% | 104 |
| 60-min | +0.52% | 53% | 105 |
| to close | -0.41% | 45% | 106 |
| Middle 50% of NRBO reactions | -2.68% to +3.47% |
|---|---|
| Median reaction (30-min) | +0.52% |
| Measured reactions | 132 |
Half of all NeuroBo Pharmaceuticals, Inc. news events land between -2.68% and +3.47% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NRBO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NRBO's baseline. Nothing else.
Recent NRBO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K MetaVia Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form D MetaVia Inc. | SEC filing · Form D | SEC EDGAR | — | — | |
| Form 10-Q MetaVia Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form EFFECT MetaVia Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form POS AM MetaVia Inc. | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 MetaVia Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-K MetaVia Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K MetaVia Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing | Press release | Accesswire | — | — | |
| Form 8-K MetaVia Inc. For: Nov 29 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K NeuroBo Pharmaceuticals, For: Nov 15 | SEC filing · Form 8-K | SEC EDGAR | +7.03% | +4.05% | |
| NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases | Press release | PR Newswire | +7.03% | +4.05% | |
| NeuroBo Pharmaceuticals to Participate in Investor Conferences in November | Press release | PR Newswire | — | +0.79% | |
| NeuroBo Pharmaceuticals to Present at the November 21st Virtual Investor Summit Microcap Event | Press release | Accesswire | -1.70% | -9.49% | |
| Form 10-Q NeuroBo Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.85% | +3.70% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.28% | |
| NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | PR Newswire | +0.00% | +4.28% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +7.20% | +1.20% | |
| NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH | Press release | PR Newswire | +7.20% | +1.20% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +0.70% | +1.89% | |
| NeuroBo Pharmaceuticals to Participate in Investor Conferences in October | Press release | PR Newswire | +0.00% | -6.98% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | -8.12% | |
| NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity | Press release | PR Newswire | -1.74% | -8.12% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | +0.61% | -3.33% | |
| NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | Press release | PR Newswire | -2.41% | -6.18% | |
| Form DEF 14A NeuroBo Pharmaceuticals, For: Sep 18 | SEC filing · Form DEF | SEC EDGAR | — | -1.62% | |
| Form 10-Q NeuroBo Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.98% | +3.45% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +3.27% | +6.27% | |
| NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | PR Newswire | +3.27% | +6.27% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -7.05% | -1.30% | |
| NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity | Press release | PR Newswire | -7.05% | -1.30% | |
| Form PRE 14A NeuroBo Pharmaceuticals, For: Sep 18 | SEC filing · Form PRE | SEC EDGAR | — | +0.53% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -1.88% | +3.02% | |
| NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity | Press release | PR Newswire | -1.88% | +3.02% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.07% | |
| NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 | Press release | PR Newswire | +0.00% | -3.07% | |
| Form EFFECT NeuroBo Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.48% | -0.61% | |
| Form S-1 NeuroBo Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | — | -5.25% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.17% | |
| NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July | Press release | PR Newswire | +0.00% | +3.56% | |
| Form D NeuroBo Pharmaceuticals, | SEC filing · Form D | SEC EDGAR | -3.17% | -1.06% | |
| Form 8-K NeuroBo Pharmaceuticals, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +5.43% | -0.41% | |
| NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity | Press release | PR Newswire | +5.43% | -0.41% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NRBO section they belong to.
Where else NRBO is measured.
NRBO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NeuroBo Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled NRBO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 132 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of NRBO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NRBO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.